45 jobs are to be created at a biopharmaceutical company in west Dublin.

Mallinckrodt is to create the jobs at a new €45m state of the art plant in Blanchardstown.

While some 300 jobs will be created in the construction phase.

The new facility will include two buildings, and additional areas for future investment on a c.4.85 hectare site.

Mallinckrodt employs more than 120 people at its existing manufacturing site in Dublin.

The firm provides treatment options for a wide variety of health conditions, with a particular focus on autoimmune and rare diseases.

This latest move brings capital investment by the company in Ireland to more than €165m.

Speaking at the announcement, the Tánaiste, Joan Burton said: "Today’s announcement represents a significant development, both for the wider Dublin region and for Ireland Inc. Mallinckrodt has had a strong and valued presence in Ireland for over 20 years and these plans for this new site support our drive for job creation."

Mark Trudeau, CEO and president of Mallinckrodt, added: "Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland."